Compare RENT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | MCRB |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 162.7M |
| IPO Year | 2021 | 2015 |
| Metric | RENT | MCRB |
|---|---|---|
| Price | $8.85 | $15.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | ★ 341.1K | 89.9K |
| Earning Date | 12-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.35 | 0.62 |
| Revenue | ★ $314,500,000.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | ★ $3.49 | $24.71 |
| Revenue Growth | ★ 2.91 | N/A |
| 52 Week Low | $3.69 | $6.53 |
| 52 Week High | $10.11 | $29.98 |
| Indicator | RENT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 72.17 | 42.87 |
| Support Level | $7.88 | $14.03 |
| Resistance Level | $9.30 | $15.41 |
| Average True Range (ATR) | 0.95 | 0.88 |
| MACD | 0.16 | -0.15 |
| Stochastic Oscillator | 85.50 | 30.49 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.